Ocular Surface Disease Treatments in the Pipeline - Takeaways - MDSpire

Ocular Surface Disease Treatments in the Pipeline

Potential treatments address inflammation and tear production, offer alternative mechanisms of action, or address a subset of dry eye.

  • By

  • Bela Parekh, MD

  • Jai G. Parekh, MD, MBA, FAAO

  • May 1, 2025

  • 7 min

Share

  • 1

    The prevalence of dry eye disease (DED) exceeds 20 million in the U.S. and 350 million globally, highlighting its significant impact.

  • 2

    Recent advancements in ocular surface disease (OSD) treatments include novel mechanisms targeting inflammation and tear production.

  • 3

    Bausch + Lomb's Miebo and Tarsus Pharmaceutical's Xdemvy represent innovative approaches to treating evaporative eye disease and Demodex blepharitis.

  • 4

    Emerging therapies, such as AbbVie's reproxalap and Alcon's AR-15512, focus on novel inflammatory pathways and improved patient compliance.

  • 5

    The future of OSD treatment promises targeted therapies and enhanced diagnostics, aiming to improve outcomes for millions suffering from chronic conditions.

Original Source(s)

Ocular Surface Disease Treatments in the Pipeline

  • by Bela Parekh, MD, Jai G. Parekh, MD, MBA, FAAO

  • May 1, 2025

Related Content

Creation and assessment of a predictive model for dry eye disease risk in myopic pediatric patients

When Vision Fluctuates, Look to the Tear Film First

Dr. Theriot discusses the differences between natural tear film and artificial tears—and why the change in moniker to "lubricating drops" is appropriate.

Insights into the quality and guideline consistency of dry eye disease treatment videos on Chinese short-video platforms